List view / Grid view
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Researchers have developed a new method for comparing CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer.
A team of scientists have 3D bioprinted breast cancer tumours and treated them in a new study, offering greater understanding of the disease.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
The scientists say that shutting down the EBAG9 gene allows the body to destroy tumour cells earlier and more radically.
Researchers have shown that a synthetic IL-9 receptor allows T cells to fight against cancer without the need for chemotherapy or radiation.
The Mark Foundation for Cancer Research awards ~$12 million to Cancer Grand Challenges Team to develop new immunotherapies for childhood solid tumours.
Read this free application note where we look at the CTS TrueCut Cas9 Protein, from its detailed quality specifications to its performance in primary T cells.
A new study in mice has shown blood cancer treatment with protein interleukin-7 revs up T-cell immunotherapy.
A new study has highlighted that the interferon gamma receptor pathway is necessary for CAR T-cell mediated killing in solid tumours.
